China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a China-based Phase I clinical study for its drug candidate GZR101. The first-in-human study aims to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of the GZR101 injection and its component GZR33.
Drug Details and Mechanism
GZR101 is a dual-insulin compound preparation combining long-acting basal insulin GZR33 and fast-acting insulin aspart, under development for diabetes treatment. It is designed to simulate the biphasic pattern of physiological insulin secretion with once-daily administration. This approach takes into account both fasting and postprandial blood sugar control, aiming to stabilize blood sugar levels.
Potential Benefits
The drug is expected to improve the rate of glycemic control while simplifying treatment regimens. By doing so, it aims to enhance patient compliance, reduce the treatment burden, optimize long-term diabetes management, and help reduce or delay the occurrence of complications associated with the disease.-Fineline Info & Tech
